Sarepta Therapeutics, Inc. SRPT Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Sarepta Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s cash ratio?
- Sarepta Therapeutics, Inc. (SRPT) reported cash ratio of 0.9× in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s cash ratio changed year-over-year?
- Sarepta Therapeutics, Inc.'s cash ratio increased by 134.0% year-over-year, from 0.4× to 0.9×.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s cash ratio has grown at a -27.3% compound annual growth rate (CAGR), from 3.6× to 0.7×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.